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1. Introduction
Melanoma is a complex disease with both genetic and epigenetic components [1-3]. Once
melanoma has formed distant metastases, melanoma patients have generally poor prognoses;
less than 10% of these patients will survive 10 years [4]. For many years, treatment with the
cytotoxic drug dacarbazine was the standard treatment for patients with metastatic melanoma,
but the response rates were low and varied from 5-20% [4]. Intense research efforts on
understanding the molecular mechanisms of melanoma progression led to the discovery and
the approval by the FDA of two new drugs in 2011, vemurafenib and ipilimumab, which raised
great hopes among melanoma patients [5-12]. Although treatment with vemurafenib has
resulted in high overall responses rates [11], resistance against the drug appeared in treated
melanoma patients within a year of treatment, leading to tumor regrowth [13-16]. On the other
hand, treatment with ipilimumab does not result in resistance but can produce life threatening
autoimmune adverse effects [17]. In addition, ipilimumab works best in patients whose tumors
present abundant tumor infiltrated immune cells [18]. It is therefore essential to identify new
therapeutic targets in melanoma.
One potential therapeutic target is the receptor for advanced glycation end products (RAGE).
A possible role of RAGE in melanoma is emerging and has been the topic of a growing number
of studies in the past decade [19-25]. These studies will be reviewed here and we will also
discuss the RAGE ligands that play important roles in melanoma progression.
2. The Receptor for Advanced Glycation End Products (RAGE)
2.1. RAGE function
RAGE is an immunoglobulin-like cell-surface receptor that is involved in a large number of
pathologies, including Alzheimer’s disease, cancer, infectious diseases and complications of
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
diabetes [31-38]. The ligands of RAGE are numerous (Table 1) and belong to distinct families
of molecules. However, they also share structural features such as the propensity to form
oligomers [39]. It is believed that RAGE recognizes similar structural elements or patterns
within its numerous ligands and therefore RAGE is described as a pattern recognition receptor
[40, 41].
Figure 1. Schematic representation of RAGE. The extracellular part of RAGE is composed of three distinct immunoglo‐
bulin-like domains (V, C1 and C2). The V and C1 domains form a structural and functional unit [26]. Most ligands
interact with the V-C1 domain. Four adaptor molecules have been suggested to bind to the intracellular domain of
RAGE: ERK1/2 [27], diaphanous-1 (Dia-1) [28], TIRAP and MyD88 [29]. Following activation of RAGE by its ligands,
multiple signaling pathways (MAPK, PI3K/Akt) or molecules (NADPH oxidase, Rac-1, cdc42) are activated and lead to
the transcription of genes related to inflammation, cell proliferation and migration, and to the expression of RAGE it‐
self, resulting in a positive feedback loop [30].
The physiological role of RAGE is not yet fully understood. Studies have shown that RAGE
plays a role in the innate but not adaptive immunity and has been shown to play an important
function in peripheral nerve repair [42-44]. A characteristic of RAGE is that it is expressed at
low basal level in most tissues except in lungs where it has been suggested to exert a protective
effect [45-48]. RAGE has also been shown to modulate the auditory system in mice [49].
Several spliced isoforms of RAGE have been described. Besides full-length RAGE, presented
in Figure 1, RAGE exists as a soluble form (sRAGE) lacking the intracellular and transmem‐
brane domains. The soluble form can result either from a splicing event or from the action of
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a metalloprotease such as ADAM 10 [50-58]. Other major identified spliced isoforms lack the
N-terminal domain or present a deletion in the intracellular domain, resulting in abnormal
ligand interaction and cell signaling activities, respectively [51, 56, 59]. sRAGE has been used
in many animal experiments to validate the role of RAGE in various diseases such as Alz‐
heimer’s disease, atherosclerosis or encephalomyelitis [60-62]. Two different models explain‐
ing the mechanism of action of sRAGE have been proposed. The “classic” mechanism suggests
that sRAGE acts as a decoy receptor and interacts with circulating RAGE ligands, which results
in the absence of RAGE/ligand complex formation and RAGE activation. Recently, the group
of Fritz has proposed a second mechanism of action for sRAGE: Fritz et al. suggest that sRAGE
could form a complex with the extracellular part of another full-length receptor and that this
receptor complex would not be functional because it possesses only one intracellular domain
[63]. According to this hypothesis, RAGE can only transmit a signal if two intracellular
domains form a dimer [63].
The role of sRAGE as biomarker has also been investigated in many diseases but has resulted
in contradictory data for certain pathologies. In Alzheimer’s disease patients, the circulating
plasma levels of sRAGE have been shown to be significantly reduced compared to healthy
individuals [64]. A more detailed immunohistological examination of AD brain showed that
the reduction in sRAGE was more pronounced in the hippocampus of AD brains than normal
brains [65]. Systemic low levels of sRAGE have also been found in patients with emphysema,
a form of chronic obstructive pulmonary disease (COPD) and sRAGE is suggested to be a
biomarker for this lung disease [66, 67]. However, in diabetes, the situation is more complex
and in different studies the levels of sRAGE have been either positively or negatively correlated
with the disease (reviewed and discussed in [68])
In cancer, an association between sRAGE and the progression of cancer has also been shown.
Significantly lower levels of sRAGE have been found in lung, breast, liver or pancreatic cancer
patients than in normal individuals [69-72]. Our study of 40 melanoma human samples also
showed significantly lower transcript levels of the spliced form of RAGE in 90% of melanoma
stage III and stage IV tissue samples compared to normal samples [73].
2.2. RAGE structure and signaling
RAGE is a single transmembrane receptor with a large extracellular part comprising of three
domains that share structural features with immunoglobulin domains: a variable type (V)
domain (residues 23-119), and two constant type domains (C1: residues 120-233, and C2:
residues 234-325) (Figure 1) [74]. The V and C1 domains form a structural and functional unit
and are the site of binding of most ligands [26].
Recent studies have suggested that RAGE structure is as complex as RAGE signaling is, and
multiple conformational forms of RAGE in complex with its ligands have been proposed [75].
Recent evidence suggests that RAGE exists as a dimer on the surface of cells, in the absence of
ligand [76, 77]. It has been suggested that the interaction of RAGE with its ligands occurs
mainly through electrostatic interactions between the positive charges present on the V and
C1 domains of RAGE and the negative charges present on RAGE ligands [39, 63]. Because both
RAGE and its ligands can form oligomers, several oligomeric models of RAGE in complex
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with its ligands have been proposed to reflect the possible RAGE/ligand interactions [39, 63,
75-79]. RAGE oligomerization could occur through contacts between the V domain [80], C1
domain [80], [77] or C2 domain, [75, 79], in a ligand dependent manner [79].
RAGE signaling is complex and RAGE/ligand interaction results in the activation of multiple
signaling pathways that are ligand and tissue specific (Figure 1) [34, 81-84]. In general, RAGE
engagement by its ligand leads to the activation of key elements of the PI3K/Akt pathways or
the mitogen-activated protein (MAP) kinase signaling pathways which include ERK1/2, p38
and JNK. Small GTPases such as p21-Ras, Rac-1 or cdc42 can also be activated as a result of
RAGE activation [28, 81, 85-87]. In many cases, RAGE activation by its ligands leads to the
initiation of, and sustained inflammation through the activation of the transcription factor NF-
κB, but also AP-1, STAT-3 and CREB (Figure 1) [36-38, 68, 88].
2.3. RAGE in melanoma
A role of RAGE in melanoma progression was first suggested by Huttunen et al [19]. In their
study, the authors generated tumors in mice using the mouse melanoma B16F10 cell-line
expressing either full-length RAGE or a form of RAGE lacking the cytoplasmic domain [19].
Comparison of the number of metastases formed in the two groups of mice revealed that mice
that were implanted with cells expressing the mutant form of RAGE generated significantly
less tumors than mice implanted with cells expressing full-length RAGE. In a different study,
Abe et al. showed that the growth of xenograft tumor in mice could be reduced using anti-
RAGE antibodies [21]. We showed that RAGE overexpression in the WM115 human melanoma
cell line resulted in a significant decrease in cell proliferation, but also in a significant increase
in cell migration and invasion suggesting that RAGE can modulate different aspects of cancer
[24]. We demonstrated that the decrease in cell proliferation was accompanied with a decrease
in the activity of ERK1/2 [24] and p38 (Meghnani et al. 2014, International Journal of Biochem‐
istry and Cell Biology, in press). The recent report of Popa et al. also suggests the presence of
different oligomeric forms of RAGE with different roles and subcellular location during
melanoma progression [25].
Studies in human melanoma tissue samples have shown that RAGE was not present in all
melanoma samples but rather in a subset of samples. Hsieh et al. showed that only 20% tissue
samples showed RAGE staining [20]. Our analysis of 40 samples of human melanoma tissue
samples also showed large variations in RAGE transcripts levels, with up to 50-fold differences
between samples [22].
Other studies have identified RAGE ligands as important elements in melanoma development.
S100B has been studied in details and its role as a diagnostic marker for melanoma patients is
well established (see section 3.1.1 on S100B). Abe et al. showed that AGEs could promote the
proliferation of melanoma cells in culture [21]. Saha et al. showed that S100A8/A9 could attract
B16F10 melanoma cells to a metastatic site, in a RAGE dependent manner [23]. In addition,
our recent study showed a strong correlation between the expression of RAGE and that of its
S100 protein ligands, in mouse xenograft melanoma tumors (Meghnani et al. 2014, Interna‐
tional Journal of Biochemistry and Cell Biology, in press).
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3. RAGE ligands
Since the identification of AGEs as ligands of RAGE, the list of RAGE ligands has grown to
more than ten ligands or groups of ligands (Table 1). In this section, we will discuss the current
knowledge on ligands that have been shown to play a role in melanoma progression, with a
focus on S100 proteins.
RAGE ligand Examples of disease where the ligand is involved References
Advanced glycation end products Inflammation, cancer, Alzheimer’s disease, atherosclerosis,
aging
[74, 89-92]
S100 proteins Inflammation, cancer, aging, neurodegenerative disorders [82, 93-95]
High mobility group box 1 (HMGB-1) Cancer, inflammation, aging [34, 96-99]
Alzheimer’s β-peptide Alzheimer’s disease [32, 60]
Transthyretin Transthyretin amyloidosis [100]
Prion Prion’s disease [101, 102]
Mac-1 Diseases of the immune system [40, 103]
Complement proteins C3a and C1q Diseases of the immune system [104, 105]
Phophatidylserine Diseases of apoptosis [106, 107]
Heparan sulfate Cancer, inflammation, developmental disorder [78, 108, 109]
DNA, RNA Infectious diseases, autoimmune disorders [110]
Table 1. Non-exhaustive list of the different ligands of RAGE. The S100 proteins that are ligands of RAGE will be
described in details in section 3.1
3.1. S100 proteins
Members of the S100 protein family have amino-acid sequence and structure similarities [111,
112]. They are small calcium binding proteins and belong to the superfamily of EF-hand
proteins [111]. Restricted to vertebrates, S100 proteins show strong tissue and cell specificity
[111, 113]. Most S100 genes (S100A1 to S100A16) are located on chromosome 1 in a region that
is prone to chromosomal rearrangement, linking these S100 proteins to cancer [113]. The
presence of EF-hands within the structure of S100 proteins enable them to bind calcium with
moderate micromolar affinity [111, 112, 114, 115]. In addition to calcium, S100 proteins can
also bind zinc and copper [116, 117]. For most S100 proteins, binding to calcium results in
conformational rearrangements that allow the S100 proteins to interact with their targets [115,
117, 118]. Certain target proteins are S100 specific whereas others are shared among multiple
S100s (Reviewed in [119]).
Most S100 target proteins are intracellular [111, 112, 120]. An example of such target that plays
a role in cancer is the tumor suppressor p53 protein [121-126]. Several members of the S100
protein family (S100B, S100A1, S100A2, S100A4, S100A6 and S100A10] bind to p53 but the
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outcome of this interaction differs depending of the S100 [121-126]. S100 proteins can also be
secreted into the extracellular space through mechanisms that are not clearly understood [127,
128]. When secreted, many S100 proteins have been shown to interact with RAGE [82, 93, 129].
Many S100 proteins are found in cells constituting the epidermis [130]. S100B and S100A6 have
been found in both melanocytes and Langerhan’s cells [131-133]. S100A2, A7, A10, A11, A12
and S100A15 have been described in normal keratinocytes [131-138]. In pathophysiological
conditions, such as in inflamed keratinocytes and melanoma, many S100 proteins have been
found overexpressed [130, 136]. The next section will describe the role of these S100 proteins
in melanoma.
3.1.1. S100B
S100B is used as a prognostic marker for stage IV malignant melanoma patients [139-141].
Serum concentration of S100B increases during the disease and high levels of S100B in the
serum is indicative of a poor prognosis [139-141]. In melanoma tumors, melanoma cells are
the main cells responsible for secreting S100B [141]. Within the cells, the role of S100B is not
clearly understood but the main target of S100B appears to be the tumor suppressor p53
protein. Indeed, several studies from the group of Weber have shown that S100B interacts with
p53 in melanoma cells and tumors, resulting in p53 inhibition and increased expression of
S100B, in a negative feedback loop [142-144]. His group is currently investigating small
interfering antisense RNA inhibitors of S100B as inhibitors of melanoma tumor growth [145].
Other intracellular target proteins of S100B could also contribute to increases in cellular
proliferation and tumor growth in melanoma. For example, S100B interacts with and activates
the glycolytic enzyme fructose-1,6-biphosphate aldolase, [146]. Consequences of this activa‐
tion could be an increase in melanoma cell metabolism and glycolysis. Inhibiting melanoma
cell metabolism and glycolysis is currently been considered in clinical trials [147, 148].
Inhibiting S100B/ fructose-1,6-biphosphate aldolase could be an approach to further reduce
glycolytic activity in melanoma cells. S100B also interacts with many components of the
cytoskeleton such as tubulin [149, 150], the actin binding protein caldesmon [151] or the small
GTPase Rac1 and the cdc42 effector IQGAP1 [152]. All these proteins play important function
in malignant melanoma [153-155] and increases in S100B levels could therefore favor increases
in cell proliferation, migration and invasion through their modulation. S100B could also play
a role in melanoma cell growth through the activation of the Nuclear Dbf2 related (ndr) kinase
[156-158] and the interaction with the phosphoprotein AHNAK/desmoyokin [159-161].
As mentioned earlier, S100B is secreted from melanoma cells. The mechanisms of S100B
secretion are still poorly understood but recent studies have suggested that RAGE participates
in the translocation and secretion of several S100s including S100B [127, 128]. Similarly, the
role of RAGE/S100B in melanoma is slowly being unraveled. S100B has been shown to signal
through RAGE in a large number of diseases (reviewed in [162]) and we studied in details the
in vitro interaction of RAGE with S100B [26, 81, 163]. For example, we showed that not only
dimeric S100B but also tetrameric and hexameric S100B could interact with RAGE and signal
in cells [163]. In addition, we recently showed that overexpression of RAGE, in human WM115
melanoma cells, was accompanied by the up-regulation of S100B in these cells [24], suggesting
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a strong association between RAGE and S100B in melanoma. When the RAGE transfected
WM115 cells were implanted in mice as xenografts, we also observed higher levels of S100B
in the serum of these animals, compared to animals implanted with control WM115 cells
(Meghnani et al. 2014, International Journal of Biochemistry and Cell Biology, in press).
3.1.2. S100A2
S100A2 is mainly located in the nuclei of cells [164]. The function of S100A2 in cancer is not
clear. In certain cancers such as prostate, oral, lung and breast cancers, S100A2 has been shown
to play the role of tumor suppressor [22, 165-169], whereas in other cancers such as esophageal
squamous carcinoma, gastric, and ovarian cancer, studies indicate that it acts as tumor
promoter [170-172]. In addition, in certain cancers, such as in non-small cell lung cancer
(NSCLC), studies are contradictory since both down-and up-regulation of S100A2 have been
reported [173-175].
In melanoma, most studies reported that S100A2 plays the role of tumor suppressor [130, 132,
165, 176]. We also showed a significant reduction in S100A2 mRNA level in both stage III and
stage IV melanoma patients samples compared to control samples [22]. Additional evidences
of a tumor suppressor effect of S100A2 comes from several studies that show positive corre‐
lations between the levels of S100A2 and anti-proliferative effects of chemotherapeutic agents
in melanoma cells [177, 178]. However, our most recent study shows that xenograft melanoma
tumors overexpressing RAGE, presented a growth advantage over control tumors, and
exhibited significant higher levels of S100A2 than control tumors (Meghnani et al. 2014,
International Journal of Biochemistry and Cell Biology, in press). We observed that S100A2
was up-regulated, both at the transcript and protein levels, in the RAGE overexpressing tumors
(Meghnani et al. unpublished results). These data suggest a complex role of S100A2 in
promoting or suppressing melanoma tumor growth.
As mentioned above, S100A2 is located in the nuclei of cells and has been shown to interact
with the tumor suppressor p53, in two oral cancer cell lines (FADU and SCC-25), thereby
modulating the transcriptional activity of p53 [123]. In vitro binding studies have confirmed
the interaction between S100A2 and p53 and has shown differences in binding of p53 to S100B
and S100A2; for example, although both S100B and S100A2 could bind to the monomeric form
of p53, only S100B was able to disrupt the oligomerization of p53, suggesting different mode
of transcriptional modulation of p53 by the S100 proteins [124, 126]. In addition to interacting
with p53, S100A2 transcriptional activity is regulated by other members of the large p53 family,
such as p63 and p73, suggesting an additional level of complexity of the S100A2/p53 regulation
[179-181]. In breast cancer tissues and cells, it was shown that both the p53 homologue Np63,
and BRCA1 were important for the transcriptional activity of S100A2 [182]. These recent data
could have a large impact in understanding the molecular mechanism of melanoma because
positive correlations have been found between the BRCA1 associated protein (BAP1] and
malignant uveal and cutaneous melanoma [183-185].
We recently demonstrated that in vitro, S100A2 could interact with RAGE [22] and our recent
study showed an association between RAGE overexpression and the levels of S100A2 in
melanoma xenograft tumors (Meghnani et al. 2014, International Journal of Biochemistry and
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Cell Biology, in press). However, a direct interaction of S100A2/RAGE in melanoma cells and
tissue has yet to be demonstrated.
3.1.3. S100A4
S100A4 was initially identified from metastatic cells and was hence named metastasin [186].
Overexpression of S100A4 in multiple cell lines has been shown to increase cancer cell
invasiveness and motility [187, 188]. The role of S100A4 in cancer was further demonstrated
in S100A4-/-mice that showed delayed tumor growth, compared to control mice, when
implanted with highly metastatic mammary carcinoma cells [189, 190].
In melanoma, the role of S100A4 is complex and appears to vary during the progression of the
disease. An early study showed no significant differences in S100A4 mRNA levels between
melanoma tissue samples and control samples [165]. Our analysis of 40 samples of stage III
and stage IV melanoma tissue samples showed a significantly reduction of S100A4 mRNA in
stage IV compared to control samples [22]. Another study also reported different correlation
between the levels of S100A4 and patient survival rates during the progression of melanoma:
high levels of S100A4 in primary melanoma tumors were associated with low patient survival
rates whereas high S100A4 levels in metastatic tumors were not associated with differences in
patient survival rates, suggesting a role of S100A4 at a early stage of the disease [191].
S100A4 exerts both intra-and extracellular functions (reviewed in [192]).  Inside the cells,
S100A4 can be found in the nuclei and cytoplasm [192]. S100A4 has been shown to interact
with p53 and, as described for S100B, to disrupt p53 oligomerization [193,  194].  In vivo,
interaction of S100A4 with p53 has been shown to promote degradation of p53, resulting
in increases in tumor growth [195]. In the cytoplasm, S100A4 interacts with a large number
of proteins of the cytoskeleton such as non-muscle myosin II [196] and tropomyosin [197],
resulting in cytoskeletal reorganization, which occurs during cell migration and invasion
[198, 199].
An important property of S100A4 is that it has been found secreted in the extracellular medium
of cells and is present in the milieu of many tumor types such as breast cancer [200], ovarian
carcinoma [201], osteosarcoma [202] or adenocarcinoma tumors [203]. Many cells from normal
tissues and from tumors have been shown to release S100A4. These cells include fibroblasts,
leukocytes, and endothelial cells [192, 204]. Extracellular S100A4 has been shown to promote
tumor growth and metastasis [192], neovascularization and angiogenesis [205-207].
Two main targets of extracellular S100A4 with relevance to tumor growth and metastasis have
been identified: Annexin II and RAGE [208, 209]. Interaction of S100A4 with annexin II has
been associated with increased mechanisms of angiogenesis such as the formation of capillary-
like tubes by endothelial cells [208]. S100A4 has been shown to enhance motility of pulmonary
artery smooth muscle cells in a RAGE dependent manner [210]. Similarly, S100A4 was shown
to promote prostate and colorectal cancer tumorigenesis and metastasis in a RAGE dependent
manner [211, 212]. In melanoma, a recent study has demonstrated that S100A4 derived from
macrophages could promote lung colonization of B16F10 melanoma cells in mice, in a RAGE
dependent manner as well [213]. We have also observed that RAGE overexpression in the
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WM115 melanoma cells resulted in the up-regulation of S100A4, by the melanoma cells, in
xenograft tumors implanted in mice (Meghnani et al. 2014, International Journal of Biochem‐
istry and Cell Biology, in press).
3.1.4. S100A6
S100A6 is another member of the S100 family with a link to cancer. S100A6 was identified from
melanoma tissue samples by comparing melanocytic lesions from normal nevi [214]. S100A6
is most abundant in epithelial cells and fibroblasts but is also found, in smaller amounts, in
other cell-types such as neurons, glial cells, smooth muscle cells, cardiac myocytes, platelets
and lymphocytes [215, 216](reviewed in [217]). S100A6 has been found elevated in a large
number of cancer types which include colorectal cancer, pancreatic, hepato-cellular carcinoma,
melanoma, lung cancer and gastric cancer [165, 218-224](reviewed in [217]). In melanoma
tumor samples, a positive correlation was found between the levels of S100A6 transcripts and
the severity of the disease [165]. In animal models, S100A6 was found to correlate with the
metastatic behavior of the melanoma cells [214, 225]. We also observed higher levels of S1006,
at the transcript level, in 43% of stage III melanoma samples examined, compared to control
samples [22]. In agreement with our study, examination of another set of melanoma tissue
samples showed that 33% of the samples stained positive for S100A6 [133]. However, exami‐
nation of melanoma tumor biopsies by immunohistochemistry often shows that the expression
of S100A6 is weak and patchy, and that other non-melanoma cutaneous lesions also stain
positive for S100A6, making it difficult to use S100A6 as a diagnostic marker for melanoma
[176, 226, 227].
S100A6 has been shown to interact with both nuclear and cytoplasmic proteins. S100A6
interacts with the tumor suppressor p53 but this interaction is different than the interaction of
p53 with S100B, suggesting different regulation of the transcriptional activity of p53 by the
two S100 proteins [124, 228]. S100A6 was shown to interact with a peptide derived from cell
membrane associated annexin I, but the physiological relevance of this interaction has yet to
be demonstrated [229]. We showed that S100A6 could interact with both the VC1 and the C2
domain of RAGE, but that in human neuroblastoma, signaling was transduced through the
C2 domain [81]. The interaction of the C3S mutant form of S100A6 with the V domain of RAGE
has recently been studied in details [230]. Similarly to what we observed with S100B, S100A2
and S100A4, RAGE overexpression in the WM115 melanoma cells resulted in the up-regulation
of S100A6, by the melanoma cells, when the cells were forming xenograft tumors in nude mice,
compared to control tumors (Meghnani et al. 2014, International Journal of Biochemistry and
Cell Biology, in press).
3.1.5. S100A8/A9
S100A8 and S100A9 are mainly expressed by cells of myeloid origin such as monocytes and
macrophages, and were first described as cytokine-like proteins for their up-regulation in
inflamed tissues and inflammatory disorders [231]. Recent studies have also shown that they
play significant roles in cancer where they promote tumor growth and metastasis in a large
number of cancers such as in breast, prostate and pancreatic cancer [232-238]. In tumors, recent
studies have shown that S100A8/A9 regulates the accumulation of myeloid-derived suppres‐
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sor cells (MDSC), and also promote the expansion of these cells, resulting in increased tumor
growth [239-243].
Neither S100A8 nor S100A9 is present in significant amounts in the cells of a normal epidermis,
including melanocytes [130, 244]. Although a study described that S100A8/A9 was absent from
melanocytic lesions [244], other studies have suggested that they participate in melanoma
progression. S100A9 has been shown to promote melanoma metastases formation in a mouse
model [245]. In a different mouse model of melanoma, the levels of MDSCs correlated with
the levels of S100A9, [246]. In addition, Saha et al. recently demonstrated that tail-vein injected
B16F10 melanoma cells, that do not express S100A8 or S100A9, could migrate to S100A8/A9-
abondant lungs of uteroglobin-knockout mice [23]. The migration of the B16F10 cells occurred
along a concentration gradient of S100A8/A9, and resulted in the formation of secondary
tumors in the lungs [23].
S100A8/A9 mediates their effect through the interaction with cell surface receptors or mole‐
cules. The two pattern recognition receptors, toll-like receptor 4 (TLR-4) and RAGE, have been
shown to transmit RAGE signaling [23, 247, 248]. In certain conditions, signaling through
RAGE has been shown to require carboxylated glycans that are covalently attached to RAGE
[249, 250]. The importance of RAGE glycosylation for RAGE signaling has also been demon‐
strated for another member of the S100 protein family, S100A12 [251]. S100A8/A9 has been
shown to interact with other glycans, such as heparin or heparin sulfate glycosaminoglycans
[137]. In addition, S100A9 has also been shown to interact with and transmit signal through
EMMPIRIN [245].
3.1.6. Other S100 proteins
Other S100 proteins are found in cells of the epidermis (reviewed by [130]), and their associ‐
ation with melanoma will be briefly described in this paragraph.
S100A7 or “psoriasin” has been linked to psoriasis because of its up-regulation in this disease
[252, 253]. Although no direct role of S100A7 in melanoma has been described yet, in one study,
significantly higher levels of S100A7 were found in the urine of melanoma patients compared
to that of healthy patients [254].
S100A10 has been found expressed at various levels in melanoma tumor samples and mela‐
nocytes [22, 244]. Our recent study where we compared the levels of S100 proteins in WM115
xenografts, generated from either control WM115 cells or from RAGE overexpressing WM115
cells, showed that S100A10 was up-regulated in the RAGE overexpressing tumors (unpub‐
lished data). Comparison of the WM115-RAGE cells with control cells did not reveal any
difference in S100A10 levels between the two cell lines, suggesting that RAGE overexpression
was responsible for the up-regulation of S100A10 in the tumors. S100A10 could therefore play
a role in melanoma progression.
S100A11 can either promote tumor growth or play the role of tumor suppressor, depending
of the type of cancer (reviewed in [255]). S100A11 has been suggested to play a role in uveal
melanoma, but has not yet been linked to cutaneous melanoma [256].
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3.2. Other ligands of RAGE
3.2.1. Advanced Glycation End products (AGEs)
Among RAGE ligands, AGEs were the first group of ligands to be identified [89]. AGEs form
a group of very heterogeneous compounds since they are the result of condensation and
oxidation reactions between proteins and sugars [257]. Although the term AGE was initially
reserved for brown, fluorescent and cross-linked structures that were produced during the
Maillard reaction, such as those found in glycated collagen, it is now used to describe other
types of modifications and AGEs now include proteins containing carboxymethyllysine,
carboxymethyl hydroxylysine or pyrraline [257]. Since many types of sugars (glucose,
ribose…) can modify many proteins, the number of different structures produced by glycation
is very large. The large heterogeneity in AGE compounds renders the comparison among
studies also very difficult. When comparing the results of studies involving AGEs, it is
therefore important to know the type of AGEs used in the study.
Melanoma cells have been shown to produce high levels of reactive carbonyl species such as
glyoxal, methylglyoxal and malondialdehyde, which all can lead to the glycation of proteins,
and which have been implicated in melanoma cell proliferation and formation of metastases
[258-260]. Abe et al. investigated the effects of different AGEs (glucose-derived AGE, glycer‐
aldehyde-derived AGE, glycoaldehyde AGE, methylglyoxal-AGE, glyoxal-AGE and carbox‐
ymethyllysine-AGE) on melanoma cell proliferation, migration and invasion, and showed that
all these AGEs were strongly present in human melanoma specimen whereas they were hardly
detected in melanocytes [21]. However, the same authors showed that only certain types of
AGE compounds (glyceraldehyde-derived AGE and glycoaldehyde AGE) could stimulate the
proliferation, migration and invasion of G361 metastatic human melanoma cells in vitro. The
role of RAGE in the in vitro AGE-dependent proliferation was demonstrated with anti-RAGE
antibodies [21]. In addition, the authors showed that treatment of mice carrying G361 mela‐
noma tumors, with anti-RAGE antibodies, resulted in reduced tumor growth and formation
of lungs metastases [21]. These results strongly suggested a role of AGE/RAGE in the devel‐
opment of melanoma tumors by the G361 human melanoma cell line [21]. Our detailed study
on melanoma cell proliferation of a panel of 20 glycated proteins showed that many factors
influenced the proliferation, such as the extent of lysine modification, the percentage of β-sheet
and the oligomerization state of the glycated proteins [261]. We showed that glycated proteins
that demonstrated higher percentage of oligomeric forms, β-sheet content and modification
of lysine, promoted stronger cell proliferation that proteins that contained lower levels of
oligomers, β-sheet or lysine modification.
3.2.2. High Mobility Group Box 1 protein (HMGB1)
HMGB-1 is present in most eukaryotic cells (reviewed by [97]). It functions both as a nuclear
protein, where it binds to DNA and assists in the transcription of multiple genes, and as an
extracellular protein, where it binds to the pattern recognition receptors TLR-2, TLR-4 and
TLR-9 as well as to RAGE, thereby promoting inflammation, mediating response to infection
and injury as well as promoting cell proliferation, migration or invasion [98, 262-266]. HMGB-1
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is also described as an alarmin or damage-associated molecular pattern [267]. HMGB-1
interacts directly with a large number of transcription factors that are relevant in cancer, and
include the tumor suppressor p53, p73, the retinoblastoma protein (RB), the p50 subunit of
NF-κB and the estrogen receptor (reviewed by [268]). The release of HMGB-1 has been shown
to be triggered by necrosis or apoptosis, such as following treatment of tumors with a chemo‐
therapeutic agent [264, 266, 267].
HMGB-1 has also been shown to be released from necrotic or apoptotic melanoma cells
[269]. A recent study showed that HMGB-1 could be released from keratinocytes in culture,
or  from  murine  skin,  following  exposure  to  UV  light  [270].  Using  a  genetically  engi‐
neered mouse model of melanoma, Bald et al.  showed that UV exposure also promoted
metastasis and angiogenesis,  through HMGB-1, and TLR-4 signaling [271].  In a different
mouse  model,  Tang  et  al.  showed  the  role  of  the  HMGB-1/RAGE  axis  in  promoting
melanoma tumor growth [272]. In melanoma patients, HMGB-1 levels have also been shown
to predict patient survival rates [273].
3.2.3. Glycosaminoglycans, β2 integrin Mac-1 and phosphatidylserine
RAGE has been shown to interact  with various glycosaminoglycans such as chondroitin
sulfate, dermatan sulfate and heparin sulfate [108]. Many of these glycosaminoglycans are
abundantly present in tumor stroma and have been shown to be key players of melano‐
ma progression and metastasis formation [274, 275]. RAGE also interacts with β2 integrin
Mac-1 on leukocytes and has been shown to promote leukocyte recruitment at the site of
inflammation [40].  The interaction between RAGE and Mac-1  is  dependent  of  the  pres‐
ence of cations, and has been shown to be significantly augmented by the presence of S100B.
In a different study, S100A9 has also been shown to activate β2 integrin Mac-1 on neutro‐
phils  suggesting that  other S100 proteins could also participate to the complex between
Mac-1 and RAGE [276]. Leukocyte recruitment at tumor sites is an important process that
allows cytotoxic T-cells to infiltrate tumors and to help in the elimination of cancer cells
[277].  In  melanoma,  success  of  the  therapy  with  interleukin-2  (IL-2)  is  based  on  the
infiltration of cytotoxic T-cells to the interior of the tumor [277]. The involvement of S100
proteins and RAGE in leukocyte recruitment suggests that therapeutic approaches target‐
ing RAGE should be carefully evaluated to avoid inhibiting the recruitment of cytotoxic T-
cells at the site of melanoma tumors. On the other hand, targeting RAGE could also result
in suppressing the recruitment of MDSCs, another form of leukocyte expressing β2 integrin
Mac-1 [278], at the tumor site, which would be beneficial for patients [279, 280].
RAGE has also been shown to interact with the negatively charged phospholipid phosphati‐
dylserine (PS) [106]. This interaction has direct relevance in melanoma because PS has been
shown to be exposed to the outer leaflet of the plasma membrane of cells forming melanoma
metastases [281]. An association between malignancy of melanoma and PS exposure has also
been described [281]. Further studies would be necessary to determine whether RAGE/PS
could be targeted in melanoma.
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4. Conclusion and therapeutic approaches
In the last two decades, RAGE has emerged as a new therapeutic target in a large number of
diseases. Because of the large number of ligands of RAGE that are relevant in melanoma,
targeting RAGE/ligand appears to be a promising approach. Several molecules could be used
as inhibitors and include the soluble form of the receptor (sRAGE), antibodies against RAGE
or small molecules. Both soluble RAGE and anti-RAGE antibodies have been used to demon‐
strate the role of RAGE in experimental models of a large number of diseases such as athero‐
sclerosis, Alzheimer’s disease or melanoma [21, 60, 282-286]. Two small molecule inhibitors of
RAGE are currently available. One compound PFS-ZM1 has been recently used in an experi‐
mental model of Alzheimer’s disease [287]. This inhibitor interacts with the V domain of RAGE
and blocks the interaction of amyloid β-peptide with the receptor. The second compound
(TPP488) has been evaluated for safety and efficacy, in a phase 2 study, in mild to moderate
Alzheimer’s disease patients. However, because of the large variation in the levels of RAGE
observed in melanoma tumor samples, it is currently not known whether targeting RAGE
would be efficacious in all melanoma tumors or only in the subset of tumors where it is
overexpressed. Additional studies would be necessary to answer this important question.
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